Palvella Therapeutics shares new investor deck

Palvella Therapeutics, Inc. filed a current report to note that on January 12, 2026 it posted a new corporate presentation on its website.

Accepted by SEC EDGAR 01/12/2026 - 07:00 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Palvella Therapeutics, Inc. filed a current report to note that on January 12, 2026 it posted a new corporate presentation on its website. Company representatives plan to use this presentation in meetings with investors from time to time. The presentation is also included as Exhibit 99.1 to the report, making the same information available through the SEC’s system.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Palvella Therapeutics (PVLA) disclose in this SEC report?

Palvella Therapeutics, Inc. disclosed that it posted a new corporate presentation on its website and filed it as Exhibit 99.1 for investors.

When did Palvella Therapeutics (PVLA) post its new corporate presentation?

Palvella Therapeutics posted its new corporate presentation on January 12, 2026.

How will Palvella Therapeutics (PVLA) use the new corporate presentation?

Representatives of Palvella Therapeutics will use the corporate presentation in various meetings with investors from time to time.

Where can investors find the Palvella Therapeutics (PVLA) corporate presentation?

Investors can find the corporate presentation on the company’s website and as Exhibit 99.1 attached to the SEC report.

What exhibit number contains the Palvella Therapeutics (PVLA) presentation?

The Palvella Therapeutics corporate presentation is filed as Exhibit 99.1 to the report.

What stock exchange lists Palvella Therapeutics (PVLA) common stock?

Palvella Therapeutics’ common stock, trading under the symbol PVLA, is listed on The Nasdaq Capital Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000158364800015836482026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

PALVELLA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada			001-37471	30-0784346
(State or other jurisdiction of incorporation)			(Commission File Number)	(IRS Employer Identification No.)
353 W. Lancaster Ave, Suite 200
Wayne, Pennsylvania				19087
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (484) 253-1461

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value per share		PVLA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 12, 2026, Palvella Therapeutics, Inc. (the “Company”) posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation is filed herewith as Exhibit 99.1, and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation of Palvella Therapeutics, Inc., dated January 12, 2026*
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PALVELLA THERAPEUTICS, INC.
Date:	January 12, 2026	By:	/s/ Matthew Korenberg
			Matthew Korenberg
			Chief Financial Officer